Glycosphingolipid Degradation

Total Page:16

File Type:pdf, Size:1020Kb

Glycosphingolipid Degradation Topology of modified by the addition of a phosphorylcholine moiety to form sphingomyelin or by the stepwise glycosphingolipid addition of sugar residues to form glycosphingo- lipids. The formation of sphingomyelin occurs at the lumenal face of the Golgi apparatus. In glycosphingo- degradation lipid synthesis, the first glucosyl residue is added at the cytosolic face of the Golgi apparatu9. The step- wise introduction of other sugar residues seems to be restricted to the lumenal face of Golgi membranes. The products of these reactions are then transported Glycosphingolipids (GSLs) form cell-type-specific patterns on the to the plasma membrane by exocytosis. Degradation of GSLs occurs in lysosomal compart- surface of eukaryotic cells. Degradation ofplasma-membrane- ments within the ce117. Fragments of the plasma- membrane-containing GSLs destined for degradation derived GSLs in the lysosomes after internalization through the are endocytosed and traffic through the endosomal endocytic pathway is achieved through the concerted actions of compartments to the lysosome. Here, hydrolysing enzymes cleave sugar residues sequentially to pro- hydrolysing enzymes and sphingolipid activator proteins. The latter duce ceramide, which is deacylated to sphingosine. are proteins necessary for the degradation of GSLs possessing short This can leave the lysosome and re-enter the bio- synthetic pathway or can be degraded further. To oligosaccharide chains. Some activator proteins bind to GSLs and date, all characterized, inherited diseases of GSL metabolism affect GSL degradation, and none has form water-soluble complexes, which lift out of the membrane and been described that affects biosynthesis of GSL. give the water-soluble hydrolysing enzymes access to the regions of Presumably, severe disorders affecting GSL biosyn- thesis would result in incorrect GSL patterns on the the GSL that would otherwise be obscured by the membrane. The cell surface, and these in turn would affect -morpho- genesis and embryogenesis and result in embryonic inherited deficiency of both lysosomal hydrolases and sphingolipid lethality. A study of the inherited disorders in GSL activator proteins gives rise to sphingolipid storage diseases. degradation, the lysosomal storage diseases, has provided insights into the processes involved in An analysis of these diseases suggests a new model for the topology GSL degradation, of endocytosis and lysosomal digestion, which is Topology of endocytosis and lysosomal digestion discussed in this article. Catabolism of complex GSLs derived from the plasma membrane occurs in the lysosomes after endocytosis. In the conventional model, com- ponents of the plasma membrane reach the lysosomal compartment by endocytic membrane flow via the Glycosphingolipids (GSLs) are components of the early and late endosomes (Ref. 8; Fig. 1). During this plasma membrane of eukaryotic cell+. Each GSL con- vesicular flow, molecules in the membrane are sub- tains a hydrophobic ceramide moiety, which acts as jected to a sorting process that directs some of the a membrane anchor, and a hydrophilic, extracellular molecules to the lysosomal compartment, others to oligosaccharide chain. Variations in the type, num- the Golgi apparatus and yet others back to the plasma ber and linkage of sugar residues in the oligosac- membrane9-lz. After a series of vesicle-budding and charide chain give rise to the wide range of naturally -fusion events through the endosomal compartment, occurring GSLs. These form cell-type-specific patterns the membrane fragments reach the lysosomal com- at the cell surface that change upon cell growth, dif- partment. As a consequence of endocytic membrane ferentiation, viral transformation and oncogenesis2. flow, constituents of the plasma membrane are incor- GSLs interact at the cell surface with toxins, viruses porated into the lysosomal membrane. Lysosomal and bacteria, as well as with membrane-bound recep- degradation of former components of the plasma tors and enzymes”. They are also involved in cell- membrane must then proceed selectively within the type-specific adhesion processes, and, in addition, lysosomal membrane, without destroying it. It is lipophilic products of GSL metabolism, such as difficult to see how this could occur, especially as sphingosine and ceramide, play a role in signal- the inner leaflet of the lysosomal membrane is cov- transduction events4. Finally, GSLs form a protective ered with a thick glycocalix composed of glyco- The authors are at layer on biological membranes, protecting them proteins, the so-called limps (lysosomal integral the lnstitut fiir from inappropriate degradation. membrane proteins) and lamps (lysosomal associated Organische The biosynthesis5 of sphingolipids takes place in membrane proteins)l3. Chemie und the endoplasmic reticulum (ER) and the Golgi appar- In an alternative model for the topology of endo- Biochemie der atus. The initial steps, converting L-serine into cytosis (Ref. 14; Fig. l), components of the plasma Universitlt, dihydroceramide, occur at the cytosolic face of membrane pass through the endosomal compart- Cerhard-Domagk- the ER. At present, the exact subcellular localiz- ment as intraendosomal vesicles that become intra- Str. 1, 53121 ation of the desaturation step leading from dihydro- lysosomal vesicles on reaching the lysosomes. The Bonn, Germany. ceramide to ceramide is not known. Ceramide is then vesicles are formed initially in the early endosome 98 0 1996 Elsevier Science Ltd trends in CELL BIOLOGY (Vol. 6) March 1996 \ \ J Late Golgi apparatus Golgi apparatus 4 ~ endosome ~ (3zY b Transient fusion Glycocalix Glycocalix membrane membrane FIGURE 1 Two models for the topology of endocytosis and lysosomal digestion of glycosphingolipids (CSLs) derived from the plasma membrane. (a) Conventional model: degradation of CSLs derived from the plasma membrane occurs selectively within the lysosomal membrane. (b) Alternative model: during endocytosis, glycolipids of the plasma membrane become incorporated into the membranes of intraendosomal vesicles (multivesicular bodies). The vesicles are transferred into the lysosomal compartment when the late endosome fuses with primary lysosomes. PM, plasma membrane; I, glycosphingolipid. by selective invagination (budding-in) of endosomal that the affected storage vesicles are in the late endo- membranes enriched for components of the plasma somal or lysosomal compartments. These compart- membrane. The surrounding endosome then passes ments are still functionally active, except that they along the endocytic pathway by way of the normal, are unable to degrade sphingolipids that have successive events of membrane fission and fusion. short oligosaccharide head groups. After comple- The intraendosomal vesicles, however, are carried mentation of the medium of these cells with the along as passengers and, normally, do not undergo missing precursor of sphingolipid activator protein, fusion and fission. When the vesicles reach the lyso- not only is the degradation block abolished, but some, glycoconjugates originating from the outer also the number and size of the storage organelles leaflet of the plasma membrane face the lysosol on are reduced (J. K. Burkhardt, S. Hiittler, A. Klein, the outer leaflet of intralysosomal vesicles and, thus, W. Mobius, A. Habermann, G. Griffiths and K. Sandhoff, are in the correct orientation for degradation. unpublished). According to this model, there is no glycocalix block- To date, budding-in of vesicles at the early endo- ing the action of hydrolases. This hypothesis is some stage has not been observed by microscopy. supported by a series of observations: This membrane fission event is thought to occur l Multivesicular bodies are observed at the level of since it would explain both the occurrence of intra- the early and late endosomal reticulum12~15-17. lysosomal vesicles and the selective degradation of * The epidermal growth factor receptor derived GSLs derived from the plasma membrane, in contrast from the plasma membrane and internalized into to those of the lysosomal membrane. lysosomes of hepatocytes is not integrated into the Within the lysosome, degradation of GSLs occurs lysosomal membrane18. by the stepwise action of specific acid exohydrolases * Spherical multivesicular bodies are the predomi- (Ref. 7; Fig. 2). More than ten different exohydro- nant endocytic compartments in HEp-2 cells. lases are involved in this process. If any of these Moreover, these multivesicular bodies mature within enzymes is deficient, the corresponding lipid sub- 60 to 90 min into lysosomes that still contain inter- strate accumulates and is stored in the lysosomal nal vesicles19. compartment. In the inherited sphingolipid storage * Multivesicular storage bodies accumulate in cells diseases, accumulation of lipids occurs mainly in from patients with sphingolipid storage diseases. those cell types and organs in which the lipids are They were observed almost 30 years ago in cerebral predominantly synthesized. In Tay-Sachs disease, cells from patients with GM1 gangliosidosiszO. for example, B-hexosaminidase A is deficient. This Multivesicular storage bodies also occur in cells (e.g. causes accumulation of the ganglioside GM2 in Kupffer cells and fibroblasts) of a patient with neuronal cells, the main sites for synthesis of another sphingolipid storage disease - giving a com- gangliosides (sialic acid-containing GSLs). In this bined activator protein deficiency2Q2. Analysis of autosomal recessive, lethal disease, the
Recommended publications
  • From Genes to Systems: New Global Strategies for the Characterization of NCL Biology ⁎ Anu Jalanko A, , Jaana Tyynelä B, Leena Peltonen A,C,D,E
    View metadata, citation and similar papers at core.ac.uk brought to you by CORE provided by Elsevier - Publisher Connector Biochimica et Biophysica Acta 1762 (2006) 934–944 www.elsevier.com/locate/bbadis Review From genes to systems: New global strategies for the characterization of NCL biology ⁎ Anu Jalanko a, , Jaana Tyynelä b, Leena Peltonen a,c,d,e a National Public Health Institute, Department of Molecular Medicine, Biomedicum Helsinki, P.O. Box 104, 00251 Helsinki, Finland b University of Helsinki, Institute of Biomedicine/Biochemistry, Finland c University of Helsinki, Department of Medical Genetics, Finland d Research Programme of Molecular Medicine and Research Programme of Neurosciences, Biomedicum Helsinki, Finland e The Broad Institute of MIT and Harvard, Cambridge, Massachusetts, USA Received 22 April 2006; received in revised form 1 September 2006; accepted 5 September 2006 Available online 12 September 2006 Abstract Neuronal ceroid lipofuscinoses (NCL) are rare neurological disorders with a uniform phenotype, caused by mutations in seven known genes. NCL provide a unique model to characterize molecular pathways critical for normal neuronal development and pathological neuronal degeneration. Systems biology based approach utilizes the rapidly developing tools of genomics, proteomics, lipidomics and metabolomics and aims at thorough understanding of the functions of cells, tissues and whole organisms by molecular analysis and biocomputing-assisted modeling. The systems level understanding of NCL is now possible by utilizing different model organisms. Initial work has revealed disturbed metabolic pathways in several NCL disorders and most analyses have utilized the infantile (INCL/CLN1) and juvenile (JNCL/CLN3) disease modeling and utilized mainly human and mouse samples.
    [Show full text]
  • Sphingolipid Metabolism Diseases ⁎ Thomas Kolter, Konrad Sandhoff
    View metadata, citation and similar papers at core.ac.uk brought to you by CORE provided by Elsevier - Publisher Connector Biochimica et Biophysica Acta 1758 (2006) 2057–2079 www.elsevier.com/locate/bbamem Review Sphingolipid metabolism diseases ⁎ Thomas Kolter, Konrad Sandhoff Kekulé-Institut für Organische Chemie und Biochemie der Universität, Gerhard-Domagk-Str. 1, D-53121 Bonn, Germany Received 23 December 2005; received in revised form 26 April 2006; accepted 23 May 2006 Available online 14 June 2006 Abstract Human diseases caused by alterations in the metabolism of sphingolipids or glycosphingolipids are mainly disorders of the degradation of these compounds. The sphingolipidoses are a group of monogenic inherited diseases caused by defects in the system of lysosomal sphingolipid degradation, with subsequent accumulation of non-degradable storage material in one or more organs. Most sphingolipidoses are associated with high mortality. Both, the ratio of substrate influx into the lysosomes and the reduced degradative capacity can be addressed by therapeutic approaches. In addition to symptomatic treatments, the current strategies for restoration of the reduced substrate degradation within the lysosome are enzyme replacement therapy (ERT), cell-mediated therapy (CMT) including bone marrow transplantation (BMT) and cell-mediated “cross correction”, gene therapy, and enzyme-enhancement therapy with chemical chaperones. The reduction of substrate influx into the lysosomes can be achieved by substrate reduction therapy. Patients suffering from the attenuated form (type 1) of Gaucher disease and from Fabry disease have been successfully treated with ERT. © 2006 Elsevier B.V. All rights reserved. Keywords: Ceramide; Lysosomal storage disease; Saposin; Sphingolipidose Contents 1. Sphingolipid structure, function and biosynthesis ..........................................2058 1.1.
    [Show full text]
  • Glycosphingolipid Metabolism in Cell Fate Specification Domenico Russo1,*, Laura Capolupo1,2, Jaipreet Singh Loomba1,2, Lucia Sticco1 and Giovanni D’Angelo1,2,*
    © 2018. Published by The Company of Biologists Ltd | Journal of Cell Science (2018) 131, jcs219204. doi:10.1242/jcs.219204 REVIEW Glycosphingolipid metabolism in cell fate specification Domenico Russo1,*, Laura Capolupo1,2, Jaipreet Singh Loomba1,2, Lucia Sticco1 and Giovanni D’Angelo1,2,* ABSTRACT anchoring. Specifically at the PM, sphingolipids participate in Glycosphingolipids (GSLs) are ubiquitous components of eukaryotic signaling events by recruiting signaling molecules to, or plasma membranes that consist of a ceramide backbone linked to a sequestering them at, membrane microdomains for the modulation glycan moiety. Both the ceramide and the glycan parts of GSLs display of their activities and for their processing into the endocytic cycle structural variations that result in a remarkable repertoire of diverse (Holthuis and Menon, 2014; Holthuis et al., 2001; Simons and compounds. This diversity of GSLs is exploited during embryogenesis, Ikonen, 1997). Given these properties, sphingolipids are proposed to when different GSLs are produced at specific developmental stages and function as fundamental membrane organizers and to make up along several differentiation trajectories. Importantly, plasma membrane the fabric of eukaryotic PMs in order to influence the interaction receptors interact with GSLsto modify their activities. Consequently, two with the extracellular environment (Hannun and Obeid, 2018; otherwise identical cells can respond differently to the same stimulus Holthuis et al., 2001). owing to their different GSL composition. The metabolic reprograming of Interestingly, different cell types exhibit a specific sphingolipid GSLs is in fact a necessary part of developmental programs, as its array at their PMs (Hakomori, 2003; Ngamukote et al., 2007) impairment results in developmental failure or tissue-specific defects.
    [Show full text]
  • Building a Metabolic Bridge Between Glycolysis and Sphingolipid Biosynthesis : Implications in Cancer
    University of Louisville ThinkIR: The University of Louisville's Institutional Repository Electronic Theses and Dissertations 8-2014 Building a metabolic bridge between glycolysis and sphingolipid biosynthesis : implications in cancer. Morgan L. Stathem University of Louisville Follow this and additional works at: https://ir.library.louisville.edu/etd Part of the Pharmacy and Pharmaceutical Sciences Commons Recommended Citation Stathem, Morgan L., "Building a metabolic bridge between glycolysis and sphingolipid biosynthesis : implications in cancer." (2014). Electronic Theses and Dissertations. Paper 1374. https://doi.org/10.18297/etd/1374 This Master's Thesis is brought to you for free and open access by ThinkIR: The nivU ersity of Louisville's Institutional Repository. It has been accepted for inclusion in Electronic Theses and Dissertations by an authorized administrator of ThinkIR: The nivU ersity of Louisville's Institutional Repository. This title appears here courtesy of the author, who has retained all other copyrights. For more information, please contact [email protected]. BUILDING A METABOLIC BRIDGE BETWEEN GLYCOLYSIS AND SPHINGOLIPID BIOSYNTHESIS: IMPLICATIONS IN CANCER By Morgan L. Stathem B.S., University of Georgia, 2010 A Thesis Submitted to the Faculty of the School of Medicine of the University of Louisville In Partial Fulfillment of the Requirements for the Degree of Master of Science Department of Pharmacology and Toxicology University of Louisville Louisville, KY August 2014 BUILDING A METABOLIC BRIDGE BETWEEN GLYCOLYSIS AND SPHINGOLIPID BIOSYNTHESIS: IMPLICATIONS IN CANCER By Morgan L. Stathem B.S., University of Georgia, 2010 Thesis Approved on 08/07/2014 by the following Thesis Committee: __________________________________ Leah Siskind, Ph.D. __________________________________ Levi Beverly, Ph.D.
    [Show full text]
  • Targeting the Sphingosine Kinase/Sphingosine-1-Phosphate Signaling Axis in Drug Discovery for Cancer Therapy
    cancers Review Targeting the Sphingosine Kinase/Sphingosine-1-Phosphate Signaling Axis in Drug Discovery for Cancer Therapy Preeti Gupta 1, Aaliya Taiyab 1 , Afzal Hussain 2, Mohamed F. Alajmi 2, Asimul Islam 1 and Md. Imtaiyaz Hassan 1,* 1 Centre for Interdisciplinary Research in Basic Sciences, Jamia Millia Islamia, Jamia Nagar, New Delhi 110025, India; [email protected] (P.G.); [email protected] (A.T.); [email protected] (A.I.) 2 Department of Pharmacognosy, College of Pharmacy, King Saud University, Riyadh 11451, Saudi Arabia; afi[email protected] (A.H.); [email protected] (M.F.A.) * Correspondence: [email protected] Simple Summary: Cancer is the prime cause of death globally. The altered stimulation of signaling pathways controlled by human kinases has often been observed in various human malignancies. The over-expression of SphK1 (a lipid kinase) and its metabolite S1P have been observed in various types of cancer and metabolic disorders, making it a potential therapeutic target. Here, we discuss the sphingolipid metabolism along with the critical enzymes involved in the pathway. The review provides comprehensive details of SphK isoforms, including their functional role, activation, and involvement in various human malignancies. An overview of different SphK inhibitors at different phases of clinical trials and can potentially be utilized as cancer therapeutics has also been reviewed. Citation: Gupta, P.; Taiyab, A.; Hussain, A.; Alajmi, M.F.; Islam, A.; Abstract: Sphingolipid metabolites have emerged as critical players in the regulation of various Hassan, M..I. Targeting the Sphingosine Kinase/Sphingosine- physiological processes. Ceramide and sphingosine induce cell growth arrest and apoptosis, whereas 1-Phosphate Signaling Axis in Drug sphingosine-1-phosphate (S1P) promotes cell proliferation and survival.
    [Show full text]
  • Download (Accessed on 10 December 2020)
    H OH metabolites OH Article Comprehensive Identification of Glycosphingolipids in Human Plasma Using Hydrophilic Interaction Liquid Chromatography— Electrospray Ionization Mass Spectrometry Karel Hoˇrejší 1,2, Robert Jirásko 1, Michaela Chocholoušková 1, Denise Wolrab 1, David Kahoun 2 and Michal Holˇcapek 1,* 1 Department of Analytical Chemistry, Faculty of Chemical Technology, University of Pardubice, Studentská 573, 532 10 Pardubice, Czech Republic; [email protected] (K.H.); [email protected] (R.J.); [email protected] (M.C.); [email protected] (D.W.) 2 Institute of Chemistry, Faculty of Science, University of South Bohemia in Ceskˇ é Budˇejovice,Branišovská 1760, 370 05 Ceskˇ é Budˇejovice,Czech Republic; [email protected] * Correspondence: [email protected]; Tel.: +420-466-037-087 Abstract: Glycosphingolipids (GSL) represent a highly heterogeneous class of lipids with many cellular functions, implicated in a wide spectrum of human diseases. Their isolation, detection, and comprehensive structural analysis is a challenging task due to the structural diversity of GSL molecules. In this work, GSL subclasses are isolated from human plasma using an optimized monophasic ethanol–water solvent system capable to recover a broad range of GSL species. Obtained Citation: Hoˇrejší,K.; Jirásko, R.; deproteinized plasma is subsequently purified and concentrated by C18-based solid-phase extraction Chocholoušková, M.; Wolrab, D.; (SPE). The hydrophilic interaction liquid chromatography coupled to electrospray ionization linear Kahoun, D.; Holˇcapek,M. ion trap tandem mass spectrometry (HILIC-ESI-LIT-MS/MS) is used for GSL analysis in the human Comprehensive Identification of plasma extract. Our results provide an in-depth profiling and structural characterization of glycosph- Glycosphingolipids in Human ingolipid and some phospholipid subclasses identified in the human plasma based on their retention Plasma Using Hydrophilic Interaction times and the interpretation of tandem mass spectra.
    [Show full text]
  • Comprehensive Profiling of Glycosphingolipid Glycans Using A
    Article Comprehensive Profiling of Glycosphingolipid Glycans using a Novel Broad Specificity Endoglycoceramidase in a High-Throughput Workflow Simone Albrecht, Saulius Vainauskas, Henning Stoeckmann, Ciara McManus, Christopher H. Taron, and Pauline Mary Rudd Anal. Chem., Just Accepted Manuscript • DOI: 10.1021/acs.analchem.6b00259 • Publication Date (Web): 01 Apr 2016 Downloaded from http://pubs.acs.org on April 6, 2016 Just Accepted “Just Accepted” manuscripts have been peer-reviewed and accepted for publication. They are posted online prior to technical editing, formatting for publication and author proofing. The American Chemical Society provides “Just Accepted” as a free service to the research community to expedite the dissemination of scientific material as soon as possible after acceptance. “Just Accepted” manuscripts appear in full in PDF format accompanied by an HTML abstract. “Just Accepted” manuscripts have been fully peer reviewed, but should not be considered the official version of record. They are accessible to all readers and citable by the Digital Object Identifier (DOI®). “Just Accepted” is an optional service offered to authors. Therefore, the “Just Accepted” Web site may not include all articles that will be published in the journal. After a manuscript is technically edited and formatted, it will be removed from the “Just Accepted” Web site and published as an ASAP article. Note that technical editing may introduce minor changes to the manuscript text and/or graphics which could affect content, and all legal disclaimers and ethical guidelines that apply to the journal pertain. ACS cannot be held responsible for errors or consequences arising from the use of information contained in these “Just Accepted” manuscripts.
    [Show full text]
  • Disorders of Sphingolipid Synthesis, Sphingolipidoses, Niemann-Pick Disease Type C and Neuronal Ceroid Lipofuscinoses
    551 38 Disorders of Sphingolipid Synthesis, Sphingolipidoses, Niemann-Pick Disease Type C and Neuronal Ceroid Lipofuscinoses Marie T. Vanier, Catherine Caillaud, Thierry Levade 38.1 Disorders of Sphingolipid Synthesis – 553 38.2 Sphingolipidoses – 556 38.3 Niemann-Pick Disease Type C – 566 38.4 Neuronal Ceroid Lipofuscinoses – 568 References – 571 J.-M. Saudubray et al. (Eds.), Inborn Metabolic Diseases, DOI 10.1007/978-3-662-49771-5_ 38 , © Springer-Verlag Berlin Heidelberg 2016 552 Chapter 38 · Disor ders of Sphingolipid Synthesis, Sphingolipidoses, Niemann-Pick Disease Type C and Neuronal Ceroid Lipofuscinoses O C 22:0 (Fatty acid) Ganglio- series a series b HN OH Sphingosine (Sphingoid base) OH βββ β βββ β Typical Ceramide (Cer) -Cer -Cer GD1a GT1b Glc ββββ βββ β Gal -Cer -Cer Globo-series GalNAc GM1a GD1b Neu5Ac βαββ -Cer Gb4 ββ β ββ β -Cer -Cer αβ β -Cer GM2 GD2 Sphingomyelin Pcholine-Cer Gb3 B4GALNT1 [SPG46] [SPG26] β β β ββ ββ CERS1-6 GBA2 -Cer -Cer ST3GAL5 -Cer -Cer So1P So Cer GM3 GD3 GlcCer - LacCer UDP-Glc UDP Gal CMP -Neu5Ac - UDP Gal PAPS Glycosphingolipids GalCer Sulfatide ββ Dihydro -Cer -Cer SO 4 Golgi Ceramide apparatus 2-OH- 2-OH-FA Acyl-CoA FA2H CERS1-6 [SPG35] CYP4F22 ω-OH- ω-OH- FA Acyl-CoA ULCFA ULCFA-CoA ULCFA GM1, GM2, GM3: monosialo- Sphinganine gangliosides Endoplasmic GD3, GD2, GD1a, GD1b: disialo-gangliosides reticulum KetoSphinganine GT1b: trisialoganglioside SPTLC1/2 [HSAN1] N-acetyl-neuraminic acid: sialic acid found in normal human cells Palmitoyl-CoA Deoxy-sphinganine + Serine +Ala or Gly Deoxymethylsphinganine 38 . Fig. 38.1 Schematic representation of the structure of the main sphingolipids , and their biosynthetic pathways.
    [Show full text]
  • Anti-GM2 Ganglioside [L55-81] Standard Size, 200 Μg, Ab00786-23.0 View Online
    Anti-GM2 ganglioside [L55-81] Standard Size, 200 μg, Ab00786-23.0 View online Anti-GM2 ganglioside [L55-81] Standard Size Ab00786-23.0 This chimeric rabbit antibody was made using the variable domain sequences of the original Human IgM format, for improved compatibility with existing reagents, assays and techniques. Isotype and Format: Rabbit IgG, Kappa Clone Number: L55-81 Alternative Name(s) of Target: UniProt Accession Number of Target Protein: Published Application(s): depleting, TLC, ELISA, IHC Published Species Reactivity: Human Immunogen: L55-81 was prepared by isolating EBV-immortalized peripheral blood B lymphocytes from a human donor with melanoma. Specificity: L55-81 binds specifically to GM2 ganglioside; this antibody shows no reactivity towards GM1, GM3, GD2 or normal tissues- the L55-81 epitope contains both a GalNAc and sialic acid bound to lactose. Ganglioside GM2 (GalNAcβ1-4(NeuNAcα2-3)Galβ1-4Glcβ-1ceramide) is a glycosphingolipid present on the cell surface and a major tumor-differentiation antigen in human melanoma and hepatoma. Application Notes: L55-81 reacts positively to melanoma cell lines with high GM2 expression (M14; M24), and shows no binding to normal cell types or cell lines M15 or M25 which have low GM2 expression and high GM3 expression. This specificity can be confirmed by ELISA and TLC immunostaining by testing a variety of gangliosides and neutral glycolipids. L55-81 is able to lyse cells from the M14 melanoma cell line (which has high GM2 expression) in the presence of human or rabbit complement, but not in the absence of complement - this was shown by a [51Cr] release assay.
    [Show full text]
  • The Glycosphingolipid, Lactosylceramide, Regulates B1-Integrin Clustering and Endocytosis
    Research Article The Glycosphingolipid, Lactosylceramide, Regulates B1-Integrin Clustering and Endocytosis Deepak K. Sharma, Jennifer C. Brown, Zhijie Cheng, Eileen L. Holicky, David L. Marks, and Richard E. Pagano Department of Biochemistry and Molecular Biology, Thoracic Diseases Research Unit, and Mayo Clinic Cancer Center, Mayo Clinic College of Medicine, Rochester, Minnesota Abstract signaling complexes (3, 5) and are also initiation sites for clathrin- independent endocytic events (3, 5, 6). Glycosphingolipids are known to play roles in integrin- mediated cell adhesion and migration; however, the mecha- One mechanism by which glycosphingolipids could affect cell nisms by which glycosphingolipids affect integrins are adhesion and migration is via their interaction with integrins. ah unknown. Here, we show that addition of the glycosphingolipid, Integrins are a family of heterodimeric, integral membrane C8-lactosylceramide (C8-LacCer), or free cholesterol to human proteins at the plasma membrane, which bind to extracellular fibroblasts at 10°C causes the formation of glycosphingolipid- matrix (ECM) proteins and cell surface ligands, and are responsible enriched plasma membrane domains as shown by visualizing a for many types of cell adhesion events (7, 8). Glycosphingolipids have fluorescent glycosphingolipid probe, BODIPY-LacCer, incorpo- been shown to directly modulate integrin-based cell attachment. For rated into the plasma membrane of living cells. Addition of C8- example, gangliosides (sialic acid–terminated glycosphingolipids) LacCer or cholesterol to cells initiated the clustering of extracted from neuroblastoma cells or atherosclerotic plaques enhance platelet adhesion via integrin binding to collagen (9–11). B -integrins within these glycosphingolipid-enriched domains 1 Gangliosides also enhance binding of integrins to the ECM in mouse and the activation of the B1-integrins as assessed using a HUTS antibody that only binds activated integrin.
    [Show full text]
  • Tay-Sachs Disease Enfermedad De Tay-Sachs Received: 10/01/2018
    Rev. Fac. Med. 2019 Vol. 67 No. 3: 511-7 511 REVIEW ARTICLE DOI: http://dx.doi.org/10.15446/revfacmed.v67n3.69742 Tay-Sachs disease Enfermedad de Tay-Sachs Received: 10/01/2018. Accepted: 14/06/2018. Carlos Andrés Gualdrón-Frías1 • Laura Tatiana Calderón-Nossa1 1 Universidad Pedagógica y Tecnológica de Colombia - Tunja Campus - Faculty of Health Sciences - School of Medicine - ACEMED-UPTC Research Group - Tunja - Colombia Corresponding author: Carlos Andrés Gualdrón-Frías. Grupo de Investigación ACEMED-UPTC, Facultad de Ciencias de la Salud, Universidad Pedagógica y Tecnológica de Colombia. Calle 24 No. 5-63, antiguo Hospital San Rafael de Tunja. Phone number: +57 8 7405626, ext.: 2908. Tunja. Colombia. Email: [email protected]. | Abstract | | Resumen | Introduction: Lysosomal storage disease is caused by the deficiency Introducción. La deficiencia de una sola hidrolasa (enzimas lisosomales) of a single hydrolase (lysosomal enzymes). GM2 gangliosidoses da como resultado una enfermedad de almacenamiento lisosomal. Las are autosomal recessive disorders caused by deficiency of gangliosidosis GM2 son trastornos autosómicos recesivos causados β-hexosaminidase and Tay-Sachs disease (TSD) is one of its three por la deficiencia de β-hexosaminidasa. La enfermedad de Tay-Sachs forms. (TSD, por sus siglas en inglés) es una de las tres presentaciones de este tipo de gangliosidosis. Objective: To perform a review of the state of the art on TSD and describe its definition, epidemiology, etiology, physiopathology, Objetivo. Realizar una revisión del estado del arte de la TSD describiendo clinical manifestations, as well as advances regarding its diagnosis su definición, epidemiología, etiología, fisiopatología, manifestaciones and treatment. clínicas y actualidades en su diagnóstico y tratamiento.
    [Show full text]
  • Low Frequency of Fabry Disease in Patients with Common Heart Disease
    ORIGINAL RESEARCH ARTICLE Low frequency of Fabry disease in patients with common heart disease Raphael Schiffmann, MD, MHSc1, Caren Swift, RN1, Nathan McNeill, PhD1, Elfrida R. Benjamin, PhD2, Jeffrey P. Castelli, PhD2, Jay Barth, MD, PhD2, Lawrence Sweetman, PhD1, Xuan Wang, PhD1 and Xiaoyang Wu, PhD2 Purpose: To test the hypothesis that undiagnosed patients with (n = 7); IVS6-22 C > T, IVS4-16 A > G, IVS2+990C > A, 5′UTR-10 Fabry disease exist among patients affected by common heart C > T(n = 4), IVS1-581 C > T, IVS1-1238 G > A, 5′UTR-30 G > A, disease. IVS2+590C > T, IVS0-12 G > A, IVS4+68A > G, IVS0-10 C > T, – Methods: Globotriaosylceramide in random whole urine using IVS2-81 77delCAGCC, IVS2-77delC. Although the pathogenicity of tandem mass spectroscopy, α-galactosidase A activity in dried several of these missense mutations and complex intronic haplotypes blood spots, and next-generation sequencing of pooled or has been controversial, none of the patients screened in this study individual genomic DNA samples supplemented by Sanger were diagnosed definitively with Fabry disease. sequencing. Conclusion: This population of patients with common heart disease Results: We tested 2,256 consecutive patients: 852 women (median did not contain a substantial number of patients with undiagnosed – – Fabry disease. GLA gene sequencing is superior to urinary age 65 years (19 95)) and 1,404 men (median age 65 years (21 92)). α The primary diagnoses were coronary artery disease (n = 994), globotriaosylceramide or -galactosidase A activity in the screening arrhythmia (n = 607), cardiomyopathy (n = 138), and valvular for Fabry disease.
    [Show full text]